James G. Taylor, MD; Deepika S. Darbari, MD; Irina Maric, MD; Zachariah McIver, MD; Diane C. Arthur, MD
Potential Conflicts of Interest:Patent pending: 12/423,750 (U.S. Application); Stock/stock options: Amgen, AstraZeneca, Bristol-Myers Squibb, Fidelity Select Biotech, General Electric, Monsanto, ATT, Chevron Corporation, Citigroup, Comcast, Entergy, Exxon Corporation, Fidelity Select Energy, Hewlett Packard, Intel, IBM, Juniper Networks, Marine Products Corp., Motorola, Proctor and Gamble, Rollins, RPC, Sysco, Tokeville Gold Fund, Traveller Companies.
Taylor JG, Darbari DS, Maric I, McIver Z, Arthur DC. Therapy-Related Acute Myelogenous Leukemia in a Hydroxyurea-Treated Patient With Sickle Cell Anemia. Ann Intern Med. 2011;155:722-724. doi: 10.7326/0003-4819-155-10-201111150-00024
Download citation file:
Published: Ann Intern Med. 2011;155(10):722-724.
This article has been corrected. The original version (PDF) is appended to this article as a supplement.
Background: Hydroxyurea is an antimetabolite that minimizes pain and prolongs survival in patients with sickle cell anemia (1). It is not widely prescribed because of concerns about late effects, including cancer (2), and its leukemogenic risk is extrapolated from its reported risk in myeloproliferative disorders (3). Few cases of leukemia in patients with sickle cell anemia have been described, and only half of them report cytogenetics (4). Acute myelogenous leukemia (AML) in patients with sickle cell anemia receiving hydroxyurea treatment is exceptionally rare, but data on its true incidence are insufficient (1, 2). Whether AML in hydroxyurea-treated patients with sickle cell anemia is coincidental or related to therapy remains an unanswered question (2).
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only